Targeting mitochondrial structure sensitizes acute myeloid Leukemia to venetoclax treatment

Xufeng Chen, Christina Glytsou, Hua Zhou, Sonali Narang, Denis E. Reyna, Andrea Lopez, Theodore Sakellaropoulos, Yixiao Gong, Andreas Kloetgen, Yoon Sing Yap, Eric Wang, Evripidis Gavathiotis, Aristotelis Tsirigos, Raoul Tibes, Iannis Aifantis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The BCL2 family plays important roles in acute myeloid leukemia (AML). Venetoclax, a selective BCL2 inhibitor, has received FDA approval for the treatment of AML. However, drug resistance ensues after prolonged treatment, highlighting the need for a greater understanding of the underlying mechanisms. Using a genome-wide CRISPR/Cas9 screen in human AML, we identified genes whose inactivation sensitizes AML blasts to venetoclax. Genes involved in mitochondrial organization and function were significantly depleted throughout our screen, including the mitochondrial chaperonin CLPB. We demonstrated that CLPB is upregulated in human AML, it is further induced upon acquisition of venetoclax resistance, and its ablation sensitizes AML to venetoclax. Mechanistically, CLPB maintains the mitochondrial cristae structure via its interaction with the cristae-shaping protein OPA1, whereas its loss promotes apoptosis by inducing cristae remodeling and mitochondrial stress responses. Overall, our data suggest that targeting mitochondrial architecture may provide a promising approach to circumvent venetoclax resistance. SIGNIFICANCE: A genome-wide CRISPR/Cas9 screen reveals genes involved in mitochondrial biological processes participate in the acquisition of venetoclax resistance. Loss of the mitochondrial protein CLPB leads to structural and functional defects of mitochondria, hence sensitizing AML cells to apoptosis. Targeting CLPB synergizes with venetoclax and the venetoclax/azacitidine combination in AML in a p53-independent manner.

Original languageEnglish (US)
Pages (from-to)890-909
Number of pages20
JournalCancer discovery
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Acute Myeloid Leukemia
Clustered Regularly Interspaced Short Palindromic Repeats
Genome
Chaperonins
Apoptosis
Biological Phenomena
Azacitidine
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
Mitochondrial Proteins
Gene Silencing
Myeloid Cells
Drug Resistance
Genes
Mitochondria
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

Chen, X., Glytsou, C., Zhou, H., Narang, S., Reyna, D. E., Lopez, A., ... Aifantis, I. (2019). Targeting mitochondrial structure sensitizes acute myeloid Leukemia to venetoclax treatment. Cancer discovery, 9(7), 890-909. https://doi.org/10.1158/2159-8290.CD-19-0117

Targeting mitochondrial structure sensitizes acute myeloid Leukemia to venetoclax treatment. / Chen, Xufeng; Glytsou, Christina; Zhou, Hua; Narang, Sonali; Reyna, Denis E.; Lopez, Andrea; Sakellaropoulos, Theodore; Gong, Yixiao; Kloetgen, Andreas; Yap, Yoon Sing; Wang, Eric; Gavathiotis, Evripidis; Tsirigos, Aristotelis; Tibes, Raoul; Aifantis, Iannis.

In: Cancer discovery, Vol. 9, No. 7, 01.07.2019, p. 890-909.

Research output: Contribution to journalArticle

Chen, X, Glytsou, C, Zhou, H, Narang, S, Reyna, DE, Lopez, A, Sakellaropoulos, T, Gong, Y, Kloetgen, A, Yap, YS, Wang, E, Gavathiotis, E, Tsirigos, A, Tibes, R & Aifantis, I 2019, 'Targeting mitochondrial structure sensitizes acute myeloid Leukemia to venetoclax treatment', Cancer discovery, vol. 9, no. 7, pp. 890-909. https://doi.org/10.1158/2159-8290.CD-19-0117
Chen, Xufeng ; Glytsou, Christina ; Zhou, Hua ; Narang, Sonali ; Reyna, Denis E. ; Lopez, Andrea ; Sakellaropoulos, Theodore ; Gong, Yixiao ; Kloetgen, Andreas ; Yap, Yoon Sing ; Wang, Eric ; Gavathiotis, Evripidis ; Tsirigos, Aristotelis ; Tibes, Raoul ; Aifantis, Iannis. / Targeting mitochondrial structure sensitizes acute myeloid Leukemia to venetoclax treatment. In: Cancer discovery. 2019 ; Vol. 9, No. 7. pp. 890-909.
@article{b96d8b47952640558a09ee069533d592,
title = "Targeting mitochondrial structure sensitizes acute myeloid Leukemia to venetoclax treatment",
abstract = "The BCL2 family plays important roles in acute myeloid leukemia (AML). Venetoclax, a selective BCL2 inhibitor, has received FDA approval for the treatment of AML. However, drug resistance ensues after prolonged treatment, highlighting the need for a greater understanding of the underlying mechanisms. Using a genome-wide CRISPR/Cas9 screen in human AML, we identified genes whose inactivation sensitizes AML blasts to venetoclax. Genes involved in mitochondrial organization and function were significantly depleted throughout our screen, including the mitochondrial chaperonin CLPB. We demonstrated that CLPB is upregulated in human AML, it is further induced upon acquisition of venetoclax resistance, and its ablation sensitizes AML to venetoclax. Mechanistically, CLPB maintains the mitochondrial cristae structure via its interaction with the cristae-shaping protein OPA1, whereas its loss promotes apoptosis by inducing cristae remodeling and mitochondrial stress responses. Overall, our data suggest that targeting mitochondrial architecture may provide a promising approach to circumvent venetoclax resistance. SIGNIFICANCE: A genome-wide CRISPR/Cas9 screen reveals genes involved in mitochondrial biological processes participate in the acquisition of venetoclax resistance. Loss of the mitochondrial protein CLPB leads to structural and functional defects of mitochondria, hence sensitizing AML cells to apoptosis. Targeting CLPB synergizes with venetoclax and the venetoclax/azacitidine combination in AML in a p53-independent manner.",
author = "Xufeng Chen and Christina Glytsou and Hua Zhou and Sonali Narang and Reyna, {Denis E.} and Andrea Lopez and Theodore Sakellaropoulos and Yixiao Gong and Andreas Kloetgen and Yap, {Yoon Sing} and Eric Wang and Evripidis Gavathiotis and Aristotelis Tsirigos and Raoul Tibes and Iannis Aifantis",
year = "2019",
month = "7",
day = "1",
doi = "10.1158/2159-8290.CD-19-0117",
language = "English (US)",
volume = "9",
pages = "890--909",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Targeting mitochondrial structure sensitizes acute myeloid Leukemia to venetoclax treatment

AU - Chen, Xufeng

AU - Glytsou, Christina

AU - Zhou, Hua

AU - Narang, Sonali

AU - Reyna, Denis E.

AU - Lopez, Andrea

AU - Sakellaropoulos, Theodore

AU - Gong, Yixiao

AU - Kloetgen, Andreas

AU - Yap, Yoon Sing

AU - Wang, Eric

AU - Gavathiotis, Evripidis

AU - Tsirigos, Aristotelis

AU - Tibes, Raoul

AU - Aifantis, Iannis

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The BCL2 family plays important roles in acute myeloid leukemia (AML). Venetoclax, a selective BCL2 inhibitor, has received FDA approval for the treatment of AML. However, drug resistance ensues after prolonged treatment, highlighting the need for a greater understanding of the underlying mechanisms. Using a genome-wide CRISPR/Cas9 screen in human AML, we identified genes whose inactivation sensitizes AML blasts to venetoclax. Genes involved in mitochondrial organization and function were significantly depleted throughout our screen, including the mitochondrial chaperonin CLPB. We demonstrated that CLPB is upregulated in human AML, it is further induced upon acquisition of venetoclax resistance, and its ablation sensitizes AML to venetoclax. Mechanistically, CLPB maintains the mitochondrial cristae structure via its interaction with the cristae-shaping protein OPA1, whereas its loss promotes apoptosis by inducing cristae remodeling and mitochondrial stress responses. Overall, our data suggest that targeting mitochondrial architecture may provide a promising approach to circumvent venetoclax resistance. SIGNIFICANCE: A genome-wide CRISPR/Cas9 screen reveals genes involved in mitochondrial biological processes participate in the acquisition of venetoclax resistance. Loss of the mitochondrial protein CLPB leads to structural and functional defects of mitochondria, hence sensitizing AML cells to apoptosis. Targeting CLPB synergizes with venetoclax and the venetoclax/azacitidine combination in AML in a p53-independent manner.

AB - The BCL2 family plays important roles in acute myeloid leukemia (AML). Venetoclax, a selective BCL2 inhibitor, has received FDA approval for the treatment of AML. However, drug resistance ensues after prolonged treatment, highlighting the need for a greater understanding of the underlying mechanisms. Using a genome-wide CRISPR/Cas9 screen in human AML, we identified genes whose inactivation sensitizes AML blasts to venetoclax. Genes involved in mitochondrial organization and function were significantly depleted throughout our screen, including the mitochondrial chaperonin CLPB. We demonstrated that CLPB is upregulated in human AML, it is further induced upon acquisition of venetoclax resistance, and its ablation sensitizes AML to venetoclax. Mechanistically, CLPB maintains the mitochondrial cristae structure via its interaction with the cristae-shaping protein OPA1, whereas its loss promotes apoptosis by inducing cristae remodeling and mitochondrial stress responses. Overall, our data suggest that targeting mitochondrial architecture may provide a promising approach to circumvent venetoclax resistance. SIGNIFICANCE: A genome-wide CRISPR/Cas9 screen reveals genes involved in mitochondrial biological processes participate in the acquisition of venetoclax resistance. Loss of the mitochondrial protein CLPB leads to structural and functional defects of mitochondria, hence sensitizing AML cells to apoptosis. Targeting CLPB synergizes with venetoclax and the venetoclax/azacitidine combination in AML in a p53-independent manner.

UR - http://www.scopus.com/inward/record.url?scp=85069267120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069267120&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-19-0117

DO - 10.1158/2159-8290.CD-19-0117

M3 - Article

C2 - 31048321

AN - SCOPUS:85069267120

VL - 9

SP - 890

EP - 909

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 7

ER -